Atara Biotherapeutics Inc
Change company Symbol lookup
Select an option...
ATRA Atara Biotherapeutics Inc
GATX GATX Corp
UAL United Airlines Holdings Inc
TEL TE Connectivity Ltd
HPGN HypGen Inc
IX Orix Corp
WHR Whirlpool Corp
PG Procter & Gamble Co
PWJAX PGIM Jennison International Opportunities Fund- Class A
MBWM Mercantile Bank Corp
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Price
Delayed
$13.34
Day's Change
0.05 (0.38%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.39
Day's Low
12.84
Volume
(Light)

Today's volume of 35,217 shares is on pace to be much lighter than ATRA's 10-day average volume of 927,839 shares.

35,217

UPDATE: Nikola downgraded at J.P. Morgan for 'tactical' reasons, including timing and valuation

2:57 pm ET March 5, 2021 (MarketWatch)
Print

Tomi Kilgore

Stock selloff comes amid broad weakness in the EV sector, after Volkswagen doubled down on its EV ambitions

Nikola Corp. was downgraded at J.P. Morgan, for what analyst Paul Coster said was for "tactical" reasons, including shorter-term concerns over valuation.

The electric vehicle maker's stock (NKLA) slumped 8.1% in afternoon trading Friday, and has now tumbled 18.7% amid a four-day losing streak.

Coster cut his rating to neutral, after being at overweight for the past eight months. He trimmed his stock price target to $30 from $33, but that new target was still more than double the recent price.

"This is something of a tactical move, based on timing of catalysts," Coster wrote in a research note for clients.

He said Nikola's fourth-quarter results (https://www.marketwatch.com/story/nikola-stock-gains-after-narrower-q4-loss-for-electric-truck-maker-11614287710) reassured investors that the company is more focused, "and has left much of the drama of 2020 behind." In addition, Nikola's Tre battery electric vehicle (BEV) truck launch is on schedule, with BEV trucks expected to be sold in the fourth quarter.

"This good news is now priced in the stock, so we step aside for now, but we believe the story should heat up again in mid/late 2021 if customer orders get announced, and as the first [fuel cell electric vehicle] prototype comes to life," Coster wrote.

What might also be weighing on sentiment, Volkswagen AG doubled down on its EV ambitions (https://www.volkswagenag.com/en/news/2021/03/volkswagen-is-accelerating-transformation-into-software-driven-m.html), saying Friday that it now expects to increase its market share of EV cars in Europe to 70% by 2030, up from its previous target of 35%. In the U.S. and China, the company said it is targeting market share of 50% in the same time.

Among other EV makers, shares of Tesla Inc. (TSLA) lost 3.9%, Nio Inc. (NIO) shed 5.9%, Workhorse Group Inc. (WKHS) dropped 7.1%, XPeng Inc. (XPEV) gave up 6.3% and Li Auto Inc. (LI) slipped 0.7% in afternoon trading on Friday.

The EV selloff comes while the Nasdaq Composite Index rose 1.1% and the S&P 500 index rallied 1.6%.

Separately, Nikola disclosed late Thursday that founder and the company's largest shareholder, Trevor Milton, sold 552,486 Nikola shares in the open market (https://www.sec.gov/Archives/edgar/data/1731289/000114036121007343/xslF345X03/form4.xml) on March 2, to raise $8.0 million. That left Milton, who surprisingly resigned as executive chairman in September, with a stake of 82,951,640 shares, or about 21.2% of the shares outstanding as of Feb. 19.

Also read: Here's what Wall Street is saying about Nikola founder's 'shocking' departure (https://www.marketwatch.com/story/heres-what-wall-street-is-saying-about-nikola-founders-shocking-departure-2020-09-21).

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

	

(END) Dow Jones Newswires

March 05, 2021 14:57 ET (19:57 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.